Literature DB >> 9497465

Bacterial keratitis in the critically ill.

B Parkin1, A Turner, E Moore, S Cook.   

Abstract

BACKGROUND: In the 4 year period (1988-91 there were nine cases of bacterial keratitis in five critically ill patients on an intensive care unit ('unit A'), all except one due to Pseudomonas aeruginosa. Many of these patients had serious ocular complications requiring surgery and all surviving patients were left with significant visual deficits. One further case of keratitis due to P aeruginosa occurred on unit A in April 1993. The problem of keratitis in ventilated patients is not unique to this unit as a further four cases in three patients from additional units in this area have been treated.
METHODS: Predisposing factors in unit A were established through subsequent investigations. It was found, in particular, that all the ocular infections were preceded by colonisation of the respiratory tract with the pathogenic organism. Recommendations concerning eye care and tracheal suctioning were adopted by unit A in 1991.
RESULTS: In the subsequent 4 years (1991-5), the frequency of isolation of pseudomonas from the respiratory tract per patient treated in unit A remained relatively high at 3.8% (153/4032). However, the conjunctival pseudomonas isolation rate has decreased significantly (p < 0.001) from 0.8% (19/2430) to 0.05% (2/4032).
CONCLUSIONS: Ventilated patients may be at risk from inoculation of pathogens into the eyes. The principal risk factor for bacterial keratitis in this series was corneal exposure secondary to conjunctival chemosis or lid damage. The adoption of simple preventative measures on unit A had a significant impact on the incidence of eye infections due to pseudomonas, despite the high proportion of patients whose respiratory tracts were colonised with the same organism. There is a need for additional research into the most effective method of eye care for ventilated patients in order to reduce the frequency of this avoidable condition.

Entities:  

Mesh:

Year:  1997        PMID: 9497465      PMCID: PMC1722071          DOI: 10.1136/bjo.81.12.1060

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

Review 1.  Systemic and endotracheal antibiotic prophylaxis of nosocomial pneumonia in ICU.

Authors:  H Lode; G Höffken; B Kemmerich; T Schaberg
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

2.  Eye infections caused by respiratory pathogens in mechanically ventilated patients.

Authors:  D Ommeslag; F Colardyn; J J De Laey
Journal:  Crit Care Med       Date:  1987-01       Impact factor: 7.598

Review 3.  Therapy of Pseudomonas aeruginosa eye infections.

Authors:  H J Thiel; K P Steuhl; G Döring
Journal:  Antibiot Chemother (1971)       Date:  1987

4.  Pseudomonas corneoscleral ulcers.

Authors:  I M Raber; P R Laibson; G H Kurz; V B Bernardino
Journal:  Am J Ophthalmol       Date:  1981-09       Impact factor: 5.258

5.  Atypical Pseudomonas corneal ulcers in semicomatose patients.

Authors:  W L Hutton; R R Sexton
Journal:  Am J Ophthalmol       Date:  1972-01       Impact factor: 5.258

Review 6.  Nosocomial infections in a pediatric intensive care unit.

Authors:  J Milliken; G A Tait; E L Ford-Jones; C M Mindorff; R Gold; G Mullins
Journal:  Crit Care Med       Date:  1988-03       Impact factor: 7.598

7.  Exogenous or endogenous reservoirs of nosocomial Pseudomonas aeruginosa and Staphylococcus aureus infections in a surgical intensive care unit.

Authors:  A Kropec; J Huebner; M Riffel; U Bayer; A Benzing; K Geiger; F D Daschner
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Nosocomial bacterial eye infections in intensive-care units.

Authors:  E Hilton; A A Adams; A Uliss; M L Lesser; S Samuels; F D Lowy
Journal:  Lancet       Date:  1983-06-11       Impact factor: 79.321

9.  Adherence of Pseudomonas aeruginosa to the mouse cornea. Epithelial v stromal adherence.

Authors:  G A Stern; D Weitzenkorn; J Valenti
Journal:  Arch Ophthalmol       Date:  1982-12

10.  The interaction between Pseudomonas aeruginosa and the corneal epithelium. An electron microscopic study.

Authors:  G A Stern; A Lubniewski; C Allen
Journal:  Arch Ophthalmol       Date:  1985-08
View more
  7 in total

1.  Preventing exposure keratopathy in the critically ill: a prospective study comparing eye care regimes.

Authors:  D G Ezra; G Lewis; M Healy; A Coombes
Journal:  Br J Ophthalmol       Date:  2005-08       Impact factor: 4.638

2.  Eye care in the intensive care unit.

Authors:  Benjamin J Hearne; Elewys G Hearne; Hugh Montgomery; Susan L Lightman
Journal:  J Intensive Care Soc       Date:  2018-03-22

3.  Randomised trial comparing ocular lubricants and polyacrylamide hydrogel dressings in the prevention of exposure keratopathy in the critically ill.

Authors:  Daniel G Ezra; Michelle P Y Chan; Lola Solebo; Aeesha P Malik; Elizabeth Crane; Andrew Coombes; Marie Healy
Journal:  Intensive Care Med       Date:  2008-09-23       Impact factor: 17.440

4.  A randomised controlled study of the efficacy of hypromellose and Lacri-Lube combination versus polyethylene/Cling wrap to prevent corneal epithelial breakdown in the semiconscious intensive care patient.

Authors:  Natasha Koroloff; Robert Boots; Jeff Lipman; Peter Thomas; Claire Rickard; Fiona Coyer
Journal:  Intensive Care Med       Date:  2004-03-10       Impact factor: 17.440

Review 5.  Foundational concepts in the biology of bacterial keratitis.

Authors:  Lawson Ung; James Chodosh
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

6.  Ocular surface disorders in intensive care unit patients.

Authors:  Tuba Berra Saritas; Banu Bozkurt; Baris Simsek; Zeynep Cakmak; Mehmet Ozdemir; Alper Yosunkaya
Journal:  ScientificWorldJournal       Date:  2013-10-29

7.  Descemetocele and bilateral, severe Pseudomonas keratitis in an intensive care unit patient with Graves' orbitopathy: A case report.

Authors:  Yun Chen Hsieh; Chun-Chen Chen
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.